Meltzer E O
Allergy and Asthma Medical Group and Research Center, San Diego, CA 92123, USA.
J Allergy Clin Immunol. 1995 May;95(5 Pt 2):1097-110. doi: 10.1016/s0091-6749(95)70213-x.
Individuals with rhinitis experience significant morbidity due to their disease. Research and clinical care to reduce this suffering are important.
To review the pharmacological agents that have been developed for the treatment of perennial rhinitis.
Literature review of human studies.
Medication classes include antihistamines, decongestants, anticholinergics, cromolyn sodium, and corticosteroids. These vary in regard to their pharmacology, efficacy, and adverse effects. Compliance and cost issues are also critical components of the therapeutic regimen.
Carefully chosen pharmacotherapy based on an understanding of the pathophysiology of the disease, knowledge of the potential of medications, and commitment to an ongoing patient/physician education and monitoring program can lead to improved well-being for individuals with perennial rhinitis.
鼻炎患者因其疾病而遭受严重痛苦。开展研究和临床护理以减轻这种痛苦非常重要。
综述已研发用于治疗常年性鼻炎的药物制剂。
对人体研究进行文献综述。
药物类别包括抗组胺药、减充血剂、抗胆碱能药、色甘酸钠和皮质类固醇。这些药物在药理学、疗效和不良反应方面各不相同。依从性和成本问题也是治疗方案的关键组成部分。
基于对疾病病理生理学的理解、对药物潜力的了解以及对持续的患者/医生教育和监测计划的承诺，精心选择药物治疗可改善常年性鼻炎患者的健康状况。
